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NON-CODING RNAS IDENTIFY THE INTRINSIC MOLECULAR SUBTYPES OF 
MUSCLE-INVASIVE BLADDER CANCER 
 
Andrea Elizabeth Ochoa, B.S. 
 
Advisory Professors: David J. McConkey, Ph.D. and Joya Chandra, Ph.D. 
 
There has been a recent explosion of genomics data in muscle-invasive 
bladder cancer (MIBC) to better understand the underlying biology of the disease 
that leads to the high amount of heterogeneity that is seen clinically. These studies 
have identified relatively stable intrinsic molecular subtypes of MIBC that show 
similarities to the basal and luminal subtypes of breast cancer. However, previous 
studies have primarily focused on protein-coding genes or DNA 
mutations/alterations.  
There is emerging evidence implicating non-coding RNAs (ncRNAs), both 
short (miRNA) and long (lncRNA), in the regulation of various biological processes 
involved in cancer development and progression. The molecular mechanisms of 
miRNAs are relatively straightforward by inhibiting their mRNA targets, but the 
molecular mechanisms of lncRNAs are largely unknown. The identification of 
miRNAs and lncRNAs that contribute to the gene expression patterns of basal and 
luminal subtypes of MIBC will add another layer of subtype regulation.  
In this work, we sought to study the differences in miRNA and lncRNA 
expression across the subtypes of MIBC. We started with TCGA’s cohort of 408 
vii 
 
tumors as a discovery cohort to identify differentially expressed miRNAs and 
lncRNAs that were specific to the basal and luminal subtypes of MIBC. We 
developed our own miRNA-sequencing data set to perform validation studies, and 
we found that the mRNA targets of the differentially expressed miRNAs were highly 
reminiscent of the already known basal and luminal subtype biology. We also 
developed bioinformatic analyses to extract lncRNA expression data that was used 
for unsupervised consensus clustering. Surprisingly, unsupervised analyses of the 
lncRNA expression data revealed two distinct clusters that exhibited more than 90% 
concordance with the subtype classifications made using mRNA expression data. 
Taken together, the results presented here suggest that miRNA expression 
profiles, or lncRNA expression profiles, could be used as an alternative strategy to 
identify MIBC subtype. These findings could have significant clinical implications in 
the development of diagnostic tools for MIBC since miRNAs and lncRNAs are both 
stably expressed in body fluids.   
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1. Introduction 
 
1.1. Bladder Cancer 
The bladder is a hollow organ that is made up of four different layers, which 
contain different cell types.  These four layers include, from innermost to outermost, 
the transitional epithelium (or urothelium), a layer of connective tissue, a layer of 
muscle, and a layer of fatty connective tissue (Figure 1) (1).  The majority of bladder 
cancers are transitional cell carcinomas (or urothelial carcinomas) because they 
arise from transitional cells in the transitional epithelium (1).   
Bladder cancers can develop into either non-muscle invasive bladder cancers 
(NMIBCs) or muscle invasive bladder cancers (MIBCs).  NMIBCs are confined to the 
transitional epithelium and connective tissue layer, and can either grow into the 
hollow center of the bladder, referred to as papillary tumors (Figure 1), or can remain 
as a flat tumor (Figure 1).  MIBCs typically appear as flat tumors that progress to 
invade through the other layers of the bladder, and can eventually spread outside of 
the bladder to nearby lymph nodes, lungs, bones or liver.   
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Figure 1: Illustration of the bladder wall.  The four layers of the bladder wall are 
depicted: transitional epithelium (urothelium), connective tissue, muscle, and fatty 
layer.  Papillary tumors are shown to grow into the hollow center of the bladder, 
while flat tumors do not, but have a propensity to invade into the deeper layers of the 
bladder wall. 
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1.1.1. Staging 
Bladder cancers are staged based on the amount of spread into the different 
layers of the bladder.  Non-invasive papillary carcinoma (Ta), non-invasive 
carcinoma in situ (Tis), and tumors that have grown into the connective tissue layer 
(T1) are all considered NMIBC.  Tumors that have grown into the muscle layer (T2), 
into the layer of fatty tissue (T3), or have spread to nearby organs (T4) are all 
considered MIBC.    
 
1.1.2. Statistics 
Bladder cancer is the fourth most common cancer in men, occurring less 
frequently in women, accounting for 5% of all new cancer cases in the United States.  
For the year 2017, the American Cancer Society estimates 79,030 new bladder 
cancer cases in the United States, and 16,870 bladder cancer related deaths.   
The 5-year relative survival outcomes for patients with bladder cancer vary from 
about 90% to 15% depending on the stage of the cancer (1).  Approximately 70% of 
bladder cancer cases are NMIBC, with roughly 25% of those progressing to develop 
into MIBC.  Patients with NMIBC have very good survival outcomes, with a 5-year 
relative survival rate around 90%, but require long-term clinical management of the 
disease as they are prone to recurrence (2).  On the other hand, patients with MIBC 
exhibit a more heterogeneous spread with 5-year relative survival rates ranging from 
63% to 15% (3).   
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1.1.3. Treatment 
Bladder cancers can be treated with surgery alone or combined with other 
treatments, such as immunotherapy or chemotherapy.  Surgery alone is often 
performed to treat NMIBCs, however new cancers can arise later in life.  MIBCs are 
typically treated with a combination of platinum-based chemotherapy either before 
(neoadjuvant) or after (adjuvant) radical cystectomy (3, 4).  Unfortunately, only about 
30% to 40% of patients respond to this treatment plan, and the only alternative 
strategy is a recently approved anti-PDL1 immune checkpoint inhibitor (5, 6).  
Therefore, it is important to develop new classification systems, and identify new 
treatable targets, to inform and improve the clinical management of the disease.   
 
1.1.4. Disease Characterization 
Several studies have shown that various gene signatures can predict tumor 
stage, metastasis and progression, however the prognostication of bladder cancer is 
largely based on pathological criteria (7).  Therefore, efforts are currently underway 
to integrate the pathologic evaluation with molecular features to get a more 
comprehensive description of a particular tumor (8).  This has led to several 
research groups focusing on molecular data to identify tumor subtypes within MIBC 
in order to quickly identify the patients who are most at risk, or to identify those who 
would most likely respond to the available treatment options. 
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1.2. Molecular Subtyping 
In 2000, Perou and colleagues realized that breast tumors exhibited different 
molecular properties affecting their responsiveness to treatments (9, 10).  In order to 
understand the diversity of breast cancers, they characterized the gene expression 
patterns from 42 unique breast cancers and sought to identify molecular subtypes.   
They used microarrays that measured the expression of 8,102 genes to study the 
gene expression patterns, and performed hierarchical clustering to group the 
samples.  They found that the molecular portraits obtained pointed towards useful 
biological interpretations, such as signaling pathways.  They identified 5 intrinsic 
subtypes of breast cancer that were related to different molecular features: basal-
like, ERBB2+, normal breast-like, luminal A, and luminal B.  They note a distinct 
difference between the two luminal subtypes, which are estrogen receptor (ER) 
positive, and the basal-like and ERBB2+ subtypes, which are ER negative, and the 
importance to treat these two subtypes as distinct diseases.   
This was the first study that explored the heterogeneity within a specific cancer 
type, and indicated that cancers of a particular organ are clinically distinct.   By 
identifying subtype membership, clinicians are able to identify potential treatment 
strategies that will work best.  By using breast cancer as a model, similar 
approaches have been taken to identify molecular subtypes of MIBC in order to 
better understand the molecular heterogeneity within the disease. 
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1.2.1. M.D.  Anderson (MDA) oneNN classifier 
Using the work done to identify intrinsic subtypes of breast cancer as a model, 
Choi and colleagues at MDA performed whole genome messenger RNA (mRNA) 
expression profiling on a cohort of 73 fresh-frozen primary MIBCs.  They used 
Illumina BeadArrays to assess the expression of over 48,000 mRNAs, performed 
unsupervised hierarchical clustering, and identified three molecular subtypes of 
MIBC.  These three subtypes are referred to as: basal, p53-like, and luminal, which 
were validated in an independent cohort of formalin-fixed paraffin embedded MIBCs 
(11).   
The basal subtype showed enrichment of genes associated with basal breast 
cancers and squamous features (11).  The basal subtype was also characterized as 
being more aggressive, often having metastatic disease at presentation, and shorter 
disease-specific and overall survival rates (11).  Basal MIBCs, similar to basal breast 
cancers, expressed high molecular weight cytokeratins (KRT5, KRT6A/B/C, KRT14) 
and mesenchymal markers (ZEB2, VIM, TWIST1/2).  Ingenuity Pathway Analysis of 
upstream regulators predicted STAT3, HIF1α, and TP63 to be transcriptional 
regulators of basal gene expression.   
The luminal subtype of MIBC expressed the epithelial marker E-cadherin and 
canonical luminal biomarkers FOXA1, GATA3, ERBB2 and KRT20.  Luminal MIBCs 
were enriched for fibroblast growth factor receptor 3 (FGFR3) mRNA expression and 
FGFR3 activating mutations, which are common features of NMIBCs.  Ingenuity 
Pathway Analysis of upstream regulators implicated peroxisome proliferator-
activated receptor, gamma (PPARG), ER and TRIM24 in the transcriptional 
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regulation of luminal MIBC.  Luminal MIBCs had PPARG activation, active PPAR 
pathway, high PPARG mRNA expression, and high expression of PPARG’s direct 
target and coactivator, fatty acid binding protein 4 (FABP4).  Overall, when 
compared to the basal subtype, the luminal tumors had significantly better overall 
and disease-specific survival.   
The p53-like subtype identified was primarily characterized by expression of an 
active p53 signature, but also expressed luminal biomarkers.  Silhouette scores 
were calculated, which is a measure of subtype stability, and showed that the p53-
like subtype was rather unstable, with 35% of the tumors calculated to be unstable.  
Despite having expression of luminal biomarkers, the p53-like tumors showed 
significantly poor overall and disease-specific survival when compared to the luminal 
tumors.  Subsequent in vitro analyses found that these MIBCs were significantly 
resistant to neoadjuvant cisplatin-based chemotherapy when compared to the other 
subtypes. 
 
1.2.2. UNC BASE47 subtype classifier 
Damrauer and colleagues at UNC also sought to identify molecular subtypes of 
MIBC.  They compiled samples from 3 different experiments and generated a meta-
dataset of 262 MIBCs.  Using whole genome expression profiling, and unsupervised 
consensus clustering, they identified 2 intrinsic subtypes of MIBC termed basal-like 
and luminal (7).  Similar to results in breast cancer, and from MIBC studies at MDA, 
the basal-like and luminal subtypes exhibited significantly different clinical outcomes, 
with the basal-like subtype showing poorer outcomes.  As a result of their analyses, 
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they developed a prediction analysis of microarrays (PAM) classifier, termed bladder 
cancer analysis of subtypes by expression (BASE47), which consisted of 47 genes 
that could accurately identify basal-like and luminal MIBCs.   
They studied the genes that were significantly differentially expressed between 
the two clusters and identified 2,393 genes.  Similar to previous findings, the basal-
like subtype expressed high molecular weight cytokeratins (KRT5, KRT6B, KRT14) 
and CD44, while the luminal subtype expressed KRT20.  The basal subtype also 
exhibited enrichment of genes involved in cell survival and movement.   
In their study, they also emphasized the similarity of the basal-like MIBC subtype 
to the basal-like breast cancer subtype, and luminal MIBC to luminal breast cancer.  
They correlated the centroid gene expression between the bladder and breast 
cancer subtypes, and identified positive correlation between basal-like MIBC and 
basal-like and normal-like breast cancers, while luminal MIBC showed positive 
correlation with the luminal A and luminal B breast cancer subtypes (7).  They also 
showed that 16% of the MIBCs shared similar characteristics to the claudin-low 
molecular subtype of breast cancer, which is characterized by low expression of 
claudins and increased expression of mesenchymal markers (7).  While all of these 
claudin-low tumors were within the basal-like subtype, they did not show differences 
in clinical outcomes when compared to the rest of the basal-like tumors.   
 
1.2.3. The Cancer Genome Atlas (TCGA) 
TCGA also performed their own analysis to identify subsets of MIBC using RNA 
sequencing, and identified four expression subtypes.  They used 129 chemotherapy-
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naive, muscle-invasive urothelial carcinomas and performed mRNA, miRNA, and 
protein expression analyses (4).   
Their Cluster I tumors were enriched for papillary morphology, FGFR3 mutations, 
FGFR3 copy number gain and elevated FGFR3 expression, suggesting that this 
subtype may respond to FGFR inhibitors.  Cluster I and Cluster II expressed high 
levels of ERBB2 and ESR2 proteins, and showed similar features of Luminal A 
breast cancer, with expression of GATA3, FOXA1, and E-cadherin.  Cluster III, 
basal/squamous-like, expressed high molecular weight cytokeratins (KRT5, KRT6, 
KRT14) and showed similarity to basal-like breast cancers and squamous cell 
cancers of the head, neck and lung (4). The Cluster IV tumors had low expression of 
luminal markers, moderate expression of basal markers, and relatively high 
expression of miR-99a and miR-100. 
 
1.2.4. Lund subtype classification 
Another group at Lund University also sought to develop a method to classify 
tumors based on molecular features.  They used 308 bladder cancer cases, and 
identified 5 major subtypes: urobasal A (UroA), genomically unstable (GU), urobasal 
B (UroB), squamous cell carcinoma-like (SCCL), and infiltrated (Infil) (8). They 
performed hierarchical clustering with 308 tumor samples and used a successive 
two group split approach to identify their clusters.  The first split identified two 
subtypes, which were treated individually to establish further divisions, resulting in 
the identification of 7 distinct subsets (8).   
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The UroA subtype was characterized by FGFR3 mutations, FGFR3 mRNA 
expression, and expression of an FGFR3 gene signature.  A majority of these 
tumors were NMIBC, contributing to their overall good prognosis.  The GU subtype 
was characterized by TP53 mutations, increased activity of late cell cycle genes, and 
expression of KRT20.  Approximately 70% of the GU tumors were pathologically 
described as being high grade.  The SCCL subtype expressed high molecular 
weight cytokeratins (KRT6A/B/C, KRT14), was associated with poor prognosis, and 
showed pathologic signs of squamous cell differentiation.   Similar to the UroA 
subtype, the UroB subtype had high frequency of FGFR3 mutations, but also 
expressed high molecular weight cytokeratins like the SCCL subtype.  It was 
suggested that the UroB tumors may be a progressed state of UroA tumors.  The 
Infil subtype had a strong immunologic signal, suggesting the presence of 
myofibroblasts, but the subtype showed quite a bit of heterogeneity because it had 
protein expression signatures similar to GU, UroB, and SCCL tumors.   
Overall, they confirmed that the identification of molecular subtype could predict 
overall prognosis, with UroA showing good prognosis, GU and Infil showing 
intermediate prognosis, and UroB and SCCL showing the worst overall survival 
outcomes.  
 
1.2.5. Summary of subtype classifications 
Four different studies identifying molecular subtypes of urothelial carcinomas are 
highlighted here.  Each group used different platforms to acquire whole genome 
expression data, different patient cohorts, and different methods to analyze the data.  
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Despite these differences, there is a remarkable amount of similarity between all of 
the classifiers.   
Using TCGA’s latest RNA-sequencing MIBC cohort (n=408) and subtype calls on 
this cohort from the above studies, we see that the data generally fall into two 
subtypes, basal and luminal (Figure 2).  The MDA identified basal tumors overlap 
substantially with the SCCL tumors identified by Lund, and encompass all of TCGA’s 
Cluster III and most of the Cluster IV tumors.  The basal-like tumors identified by 
BASE47 encompass these subtypes, but also includes approximately half of the 
MDA p53-like tumors, and half of TCGA’s Cluster II tumors.  The MDA identified 
luminal tumors overlap with the UroA and GU tumors identified by Lund, and 
encompass TCGA’s Cluster I and some of the Cluster II tumors.  The BASE47 
luminal subtype encompasses MDA’s luminal tumors, half of MDA’s p53-like tumors, 
Lund’s GU, UroA, and a small portion of the Infil subtype.  The tumors identified as 
p53-like by MDA encompass TCGA’s cluster II and Lund’s GU, UroA and Infil 
subtypes. 
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Figure 2: Summary of different subtype classifications.  Using TCGA’s cohort of 
408 tumors we compared subtype identifications from the four different groups.  
UNC’s 2 cluster solution: basal-like (red), luminal (blue); MDA’s 3 cluster solution: 
basal (red), luminal (blue), p53-like (green); Lund’s 5 cluster solution: GU (purple), 
Infil (green), SCCL (red), UroA (blue), UroB (yellow); TCGA’s 4 cluster solution: 
cluster I (blue), cluster II (green), cluster III (red), cluster IV (yellow), missing 
information (gray).   
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1.3. Non-coding RNAs (ncRNAs) 
The current understanding of the human genome is that the majority of our 
genome is transcribed but does not encode for protein.  These portions of our 
genome were previously thought to be junk in the genome. However, recently this 
“junk” has become of major interest with the hypothesis that the non-coding regions 
of our genome are important and provide a hidden layer of signals that are 
controlling various levels of gene expression.  There are many different classes of 
non-coding RNAs, including but not limited to transfer RNAs (tRNAs), ribosomal 
RNAs (rRNA), small nucleolar RNAs (snoRNAs), long non-coding RNAs (lncRNAs), 
and micro-RNAs (miRNAs).   
Non-coding RNAs have become of prime interest in studying the heterogeneity of 
disease, because of their usefulness in making clinical predictions of outcome.  
While whole genome expression profiling data based on mRNA expression has 
become particularly useful to identify molecular tumor subtype, which has the 
potential to predict prognosis and response to treatment, this has not been easily 
translated into routine clinical practice worldwide mostly due to economic and 
technical reasons.  Therefore, ncRNAs are primed to be used as potential 
biomarkers in minimally invasive clinical tests, as they have been shown to predict 
the presence of disease with high sensitivity and specificity.  In this work, two 
classes of ncRNAs are explored, lncRNAs and miRNAs, because of their aberrant 
expression in several cancer types and their accessibility and stable expression in 
bodily fluids (12). 
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1.3.1. Micro-RNAs (miRNAs) 
There are currently 1,881 annotated human miRNAs, according to miRbase 
version 21.  MiRNAs are estimated to regulate approximately 30% of all human 
genes, with one single miRNA having the ability to affect up to 200 different mRNA 
targets (13).  Due to the number of potential mRNA targets, miRNAs have been 
suggested to exert tissue-specific functions as they often target different mRNAs in 
different tissues.  MiRNAs are small, single stranded RNAs with an approximate 
length of 22 nucleotides (nts).  They have been described as critical for a wide range 
of biological processes because of their regulation of gene expression at a post-
transcriptional level.  In breast cancer, it has been suggested that miRNA detection 
in bodily fluids is far superior to mRNA profiling because of their high tissue-
specificity and stability.  The addition of miRNA expression to current molecular 
classifications may add robustness, and improve diagnosis and treatment of multiple 
disease types (12). 
MiRNAs were first discovered in 1993 with the identification of Lin-4 in the 
nematode C. elegans (14). Several years later, in 2000, the miRNA let-7 was 
identified in C. elegans (15) and was shown to have sequence conservation in 
humans (16).  The miRNA let-7 was detected in various human tissues and was 
shown to consist of 12 distinct human miRNAs within the let-7 family (15, 17).  The 
finding that let-7 was conserved across species led to a change in the research field, 
and initiated research efforts focused on understanding small ncRNAs.   
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1.3.1.1. miRNA function 
MiRNAs were found to regulate gene expression by targeting mRNAs through 
sequence specific targeting, resulting in mRNA degradation or translational 
repression.  The recognition of the target mRNA is based on the complementarity of 
seven to eight nucleotides at the 5’-end of the miRNA (seed sequence) to the 
specific motif along the 3’-untranslated sequence of the target mRNA (13).  Perfect, 
or nearly perfect, complementarity can induce degradation of the mRNA, while 
imperfect base pairing can result in translational inhibition (13).  Translational 
repression occurs more frequently and is mediated by blocking the initiation step 
therefore affecting mRNA stability (18). MiRNAs have also been described as having 
decoy abilities, which is a less studied mechanism. In a decoy state, the miRNA 
would interfere with the function of proteins by preventing interaction between 
coordinating mRNAs (19).    
 
1.3.1.2. miRNAs and cancer 
The dysregulation of miRNAs in cancer was first reported in 2002, with the 
discovery of miR-15 and miR-16 being frequently deleted in chronic lymphocytic 
leukemia (CLL) (20). Since this discovery was made there have been several 
studies showing differential miRNA expression profiles in tumor versus normal 
tissues (21, 22).   
MiRNAs have even been implicated in the initiation and progression of many 
cancers, suggesting that they play a key role in cancer biology (23).  Several studies 
have also shown that the overexpression of a single miRNA is sufficient to initiate 
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tumor development (24, 25).  Deregulated miRNAs can also influence tumorigenesis 
by decreasing or increasing the inhibition of their mRNA targets, which has led to the 
identification of oncogenic miRNAs and tumor suppressive miRNAs (13, 26).  
Oncogenic miRNAs are often upregulated in tumor tissues and target tumor 
suppressor genes, while tumor suppressive miRNAs are frequently downregulated in 
cancer and target oncogenes.  However, subsequent studies have shown that 
miRNAs are more complex and may have dual functions depending on tumor type or 
stage in progression.  Also, since miRNAs bind to their targets with partial, rather 
than perfect complementarity, there are multiple challenges with identifying mRNA 
targets in silico.   
While miRNAs are thought to act on downstream signaling, they are often 
involved in feedback loops, causing the expression of miRNA families to be 
regulated by transcription factors (27, 28).  MiRNA expression can also be regulated 
by epigenetic modifications, as demonstrated by miRNA expression changes after 
exposing cells to DNA methylation inhibitors and histone deacetylase inhibitors (29, 
30). While epigenetic modifications can control miRNAs, miRNAs have also been 
implicated in controlling epigenetic changes.  
In cancer, miRNAs have been shown to play an important role in controlling 
metastasis, which is one of the primary causes of cancer-related deaths.  There are 
multiple steps involved in the metastatic process, in which miRNAs can either 
promote or inhibit metastasis (31).  For example, miRNA-10b has been shown to 
positively regulate migration and invasion, and is capable of initiating metastasis in 
mice by targeting repressors of metastasis (32).  However, more miRNAs have been 
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implicated in metastasis suppression, including miR-335, miR-126, miR-206, and the 
miR-200 family, by targeting transcription factors involved in metastasis initiation 
(ZEB1/2, TWIST, VIM, FN1) (33, 34). 
 
1.3.1.3. miRNAs and bladder cancer 
The first indication that miRNAs were deregulated in bladder cancer occurred in 
2007, with the identification of 10 distinct miRNAs that were up-regulated in bladder 
cancers when compared to normal tissues (35).  This study identified miR-223, miR-
26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and 
miR-205 to be significantly overexpressed in bladder tumors (35).  Since this initial 
discovery, several large-scale experiments have identified differences in miRNA 
expression patterns across the different stages and grades of bladder cancer.  Low-
grade bladder cancers have been shown to have downregulation of several 
miRNAs, while high-grade bladder cancers are often associated with upregulation of 
miRNAs (36, 37).  In low-grade bladder cancers, there is downregulation of miR-145, 
miR-143, miR-99a, and miR-100, which upregulates expression of FGFR3 (Figure 3) 
(36-38).  In high-grade bladder cancers, there is downregulation of miR-145 to inhibit 
apoptosis, and upregulation of miR-21 to inhibit the p53 pathway (Figure 3) (39).  
Very few differences in miRNA expression were previously identified between high-
grade NMIBC and MIBC. 
While studies have identified differences in miRNA expression between NMIBC 
and MIBC, the reproducibility of these miRNA expression signatures has not been 
possible due to the heterogeneity of tumor specimens and research methods.  The 
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majority of miRNA studies to date in bladder cancer consist of profiling experiments 
to compare miRNA expression profiles in normal bladder versus NMIBC or MIBC 
(40).  While this is a good start, we have barely scratched the surface of the miRNAs 
involved in bladder cancer development, progression, and the intrinsic molecular 
subtypes that are present in MIBC. 
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Figure 3: miRNAs identified in low-grade and high-grade bladder cancers. 
(Left) As normal urothelium progresses into low grade bladder cancer there are 
several changes in miRNA expression.  The miRNAs in the green box are 
downregulated, and the miRNA in the red box is upregulated in low grade bladder 
cancers.  This miRNA expression pattern has been shown to induce FGFR3 
expression.  (Right) The miRNAs involved in high grade bladder cancers are distinct 
from the miRNAs identified in low grade tumors.  The miRNA expression patterns in 
high grade bladder cancers are implicated in inhibition of apoptosis and the p53 
pathway, and induction of EMT and proliferation.  
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1.3.1.4. miRNAs as biomarkers 
MiRNAs have been implicated in identifying subtypes of breast cancer since 
miRNA expression levels were shown to predict ER, progesterone receptor (PR) and 
ERBB2 receptor status in breast cancer, suggesting that miRNAs might differentiate 
between basal and luminal subtypes (41).  MiRNAs have also been associated with 
metastasis and epithelial-mesenchymal transition (EMT), suggesting that these 
miRNAs might serve as valuable biomarkers to predict metastasis and tumor 
recurrence.   
Since cancers are commonly diagnosed through invasive techniques that involve 
taking a biopsy of the tumor tissue, miRNAs have been explored as potential 
biomarkers in bodily fluids.  In cancer, the first experiment using miRNA expression 
profiles from the blood serum of patients was performed, and identified differences in 
the expression levels of three different miRNAs (42).  Given the potential of miRNAs 
to differentiate between cancer subtypes, there is a possibility that non-invasive 
techniques based on miRNA expression could not only diagnose cancer, but also 
identify tumor subtype or patients that have a high propensity to develop recurrence.   
There have been a few studies that assessed the possibility of using urine from 
bladder cancer patients to identify miRNA biomarkers, revealing the stability of 
urinary miRNAs and the potential to use them in future diagnostic assays.  
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1.3.2. Long non-coding RNAs (lncRNAs) 
The first suggestion that not all long RNA transcripts were protein-coding came 
with the identification of H19, a paternally imprinted maternally expressed transcript 
that is often deregulated in tumors (43, 44).  This led to the subsequent identification 
of other lncRNAs, such as X inactive specific transcript (XIST) (45), and growth 
arrest-specific 5 (GAS5) (46). 
There are currently over 21,000 identified lncRNAs, but there are likely more that 
have not yet been discovered since 15% of the genome remains unannotated and 
lncRNAs overlapping with protein-coding regions have not been analyzed yet (47).  
LncRNAs are arbitrarily defined as a class of non-coding RNAs that are longer than 
200 nts in length, and have been implicated in a variety of biological functions by 
regulating the expression of genes involved in cell cycle progression, apoptosis and 
differentiation (47).  While lncRNAs are implicated as biological signal transducers, 
the molecular mechanisms by which lncRNAs function still need to be elucidated.  
Due to the lack of knowledge surrounding the functions of the identified lncRNAs, 
lncRNAs are primarily characterized based on their position relative to protein-
coding genes.  Intergenic lncRNAs are the most commonly identified class of 
lncRNA, but lncRNAs can also be transcribed from exons, introns or overlapping 
regions of protein-coding genes (48).  
LncRNAs share similar length and processing to that of protein-coding genes.  
While lncRNA sequences are not well conserved across species, they do exhibit 
tissue-specific expression but are expressed at a lower level when compared to 
protein-coding genes (49).  
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1.3.2.1. LncRNA mechanisms 
While only a handful of lncRNAs have been well characterized to date, they have 
been shown to control every level of gene expression.  They have been implicated in 
transcriptional gene silencing through chromatin structure, and posttranscriptional 
gene regulation by controlling protein synthesis and RNA transport (49, 50).  In 
addition, many lncRNAs are thought to reside in the nucleus where they can actively 
regulate gene expression through chromatin remodeling complexes or potentially 
interact with the DNA itself (47).  However, the physical association between lncRNA 
and chromatin modifier or gene promoter are still unclear. 
LncRNAs appear to have a wide range of molecular functions, but they most 
likely act as a “scaffold” to assist and support the assembly of RNA-protein 
complexes (48).  LncRNAs have also been suggested to act as guides, where they 
assist in the recruitment of RNA-protein complexes to target genes (48).  LncRNAs 
may also act as a decoy by binding proteins and inhibiting the interaction between 
the sequestered protein and downstream target (48).  While lncRNAs are primarily 
implicated in downstream signaling, they may also play a role upstream to control 
transcription factors.  Overall, the mechanisms of lncRNAs are still being explored.  
 
1.3.2.2. LncRNAs and cancer 
Some of the first lncRNAs identified have been shown to be deregulated in 
human tumors when compared to normal controls, including H19 as a potential 
oncogene (43, 51-55) and GAS5 as a potential tumor suppressor (56, 57).  The idea 
that lncRNAs exhibit cancer-specific expression was further strengthened by the 
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discovery of the prostate cancer antigen 3 (PCA3) lncRNA (58).  It was found to be 
specifically overexpressed in malignant prostate tissue, and was further developed 
into a diagnostic tool (59).  Subsequently, lncRNAs have been described in major 
pathways involved in cancer formation and progression.  
To date, several studies have focused on the differential expression of lncRNAs 
in normal versus cancerous tissue, and have identified several lncRNA biomarkers 
associated with grade, lymph node metastasis and subtype classification (60). 
Overall, alterations in lncRNA expression have been associated with tumor 
formation, progression and metastasis by regulating gene expression involved in 
associated pathways.  
 
1.3.2.3. LncRNAs and bladder cancer 
There have been 6 lncRNAs that have been implicated in bladder cancer, which 
are summarized in Table 1.  The lncRNA H19 has been found to promote metastasis 
by inhibiting E-cadherin, which results in the indirect activation of pathways that 
promote EMT (53).  H19 was also shown to increase bladder cancer growth by 
directly inducing the MYC transcription factor (61). 
The metastasis associated lung adenocarcinoma transcript (MALAT1) lncRNA 
was shown to be significantly overexpressed in bladder cancers. Overexpression led 
to increased cell proliferation and EMT activation (62).  Taurine upregulated gene 1 
(TUG1) was also identified as overexpressed in bladder cancers, and was 
significantly associated with high-grade tumors (63).  When MALAT1 and TUG1 
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interact, they have been shown to regulate genes involved in growth control 
processes.  
Urothelial cancer associated 1 (UCA1) is one of the most well studied lncRNAs 
involved in bladder cancer.  It is considered to be an oncogene since it is 
overexpressed in bladder cancers.  Overexpression of UCA1 was shown to enhance 
key signaling cascades involved in cell cycle, carcinogenesis and invasion (64-66).  
There are three identified isoforms of UCA1, one of which was associated with 
cisplatin resistance and promoting tumorigenicity (67).  
The maternally expressed 3 (MEG3) lncRNA has also been identified in bladder 
cancers, where it is considered to act as a tumor suppressor by activating p53 via 
MDM2 inhibition (68).  MEG3 expression levels were shown to be significantly 
reduced in bladder cancers compared to normal controls (69), which led to 
increased cellular proliferation and autophagy activation (70).  
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LncRNAs identified in Bladder Cancer vs. Normal Controls 
   
LncRNA Function Evidence 
   
H19 Oncogene Targets E-cadherin, induces EMT 
MALAT1 Oncogene Induces cell proliferation, migration, 
EMT through WNT signaling 
SNHG16 Oncogene Positive association with chemo-
resistance and aggressive disease 
TUG1 Oncogene Associated with high-grade tumors 
and stage 
UCA1 Oncogene Promotes cell cycle, progression, 
and invasion 
MEG3 Tumor suppressor Activates p53, inhibits autophagy 
and proliferation 
 
Table 1: LncRNAs identified to have oncogenic or tumor suppressive roles in 
bladder cancer. LncRNAs previously identified in bladder cancer versus normal 
controls, and their associated role as an oncogene or tumor suppressor.   
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1.3.2.4. LncRNAs as biomarkers 
The altered expression of lncRNAs in urologic cancers, and their demonstrated 
involvement in cancer associated cellular processes, present them as attractive non-
invasive biomarker candidates. This opens up the possibility for the development of 
clinical diagnostic tools, and possibly novel therapeutic strategies.  
LncRNAs have become of interest because of their detection in bodily fluids, and 
their potential use as diagnostic or prognostic biomarkers. For example, HOX 
transcription antisense RNA (HOTAIR) was one of the first lncRNAs identified, and it 
was found to be associated with invasion and metastasis in breast cancers (12). The 
first lncRNA that was approved as a diagnostic urinary biomarker was PCA3 
expression in prostate cancer (59). In bladder cancers, UCA1 expression has been 
measured in urine sediments, resulting in a sensitive and specific diagnostic tool to 
identify bladder cancer (71).  
Since lncRNAs are expressed in a highly tissue, disease, or developmental-
specific manner, they could serve as highly specific diagnostic, prognostic, or 
predictive biomarkers. With the rising number of newly discovered lncRNAs, and the 
accumulating evidence elucidating their functionality, there is promise for their future 
use in clinical practice.  
 
1.3.3. ncRNA summary 
The conventional understanding of gene regulation in biology has centered 
around protein-coding genes.  However, over several years, evidence has 
suggested that the evolution and development of processes regulating the 
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complexity of the genome is mainly due to the regulatory potential of the noncoding 
portions of the genome (47).  Only approximately 1.5% of the genome is protein 
coding, while the non-coding regulatory elements are transcribed into non-coding 
RNA, simply indicating that ncRNAs could play a significant regulatory role in 
complex organisms.  While miRNAs are highly conserved across species and 
involved in transcriptional and posttranscriptional gene silencing through specific 
base pairing with their targets, lncRNAs are defined as transcribed RNA molecules 
greater than 200 nt in length that are poorly conserved across species and regulate 
gene expression by diverse mechanisms that are not yet fully understood (72). 
 
1.4. Rationale 
Overall, miRNAs are emerging as promising biomarkers for diagnosis, 
prognosis and response to therapy.  MiRNAs are easily accessible, affordable, and 
present the opportunity for the development of non-invasive tools for personalized 
therapy.  The accurate and convenient diagnosis for urologic cancers remains 
clinically challenging, therefore the biggest advantage to using miRNAs is that they 
are released from the tumor tissue in the plasma or urine where they can be easily 
collected and analyzed.  Understanding the biology of bladder cancer progression 
and metastasis, as well as identifying critical markers of survival, is very important 
for the long-term purpose of discovering a cure for this disease.  Given the role that 
non-coding RNAs may play in controlling the transcriptional regulation of the intrinsic 
subtypes of MIBC, we initiated the present study to explore the role of non-coding 
RNAs in the intrinsic subtypes.    
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2. Materials and Methods 
 
Contents of this chapter are based on Ochoa AE, Choi W, Su X, Siefker-Radtke A, 
Czerniak B, Dinney C, McConkey DJ.  2016.   Specific micro-RNA expression 
patterns distinguish the basal and luminal subtypes of muscle-invasive bladder 
cancer.  Oncotarget 7(49):80164-80174.   
Copyright permission not required since Oncotarget journal policy states that, 
“authors retain ownership of the copyright for their article.” 
 
2.1. Methods for Chapter 3 
2.1.1. Human Specimens 
Informed consent was obtained from all patients who contributed tumors to 
the TCGA and MD Anderson bladder cancer cohorts utilized in this study.  All of the 
genomics studies were performed in compliance with US guidelines under approved 
IRB laboratory protocols.   
 
2.1.2. Validation Cohort 
62 fresh frozen (FF) patient samples were previously analyzed by Illumina 
HTv3 BeadChip microarray (11).  The messenger RNA expression data was 
downloaded from GEO, dataset GSE48075.  The dataset was quantile normalized 
and log2-transformed.  Subsequent differential expression was performed using the 
R Bioconductor package, linear models for microarray data (limma) (73).   
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2.1.3. Ion Torrent small RNA sequencing 
The same 62 RNA samples were used to perform small RNA sequencing on 
the Ion Proton.  First, the percentage of small RNA within the total RNA sample was 
quantified using Small RNA and RNA 6000 Nano bioanalyzer chips from Agilent.  
After calculating the percentage of small RNA in the total RNA sample, we 
calculated the quantity required to reach 20 nanograms (ng) of small RNA, which 
was used for library preparation using the Ion Total RNA Seq v2 library preparation 
kit.  The small RNA library was constructed by hybridizing and ligating the RNA, 
followed by reverse transcription to yield cDNA.  The cDNA was then purified, size-
selected, and barcoded.  The resulting cDNA library was quantified with High 
Sensitivity DNA bioanalyzer chips from Agilent to determine the molar concentration 
of each library, and to calculate the percentage of library that is barcoded small 
RNAs.  The cDNA libraries were then diluted to the same molar concentration, 
pooled, and diluted to 100 picomolar (pM).  The pooled sample was then templated 
and sequenced with the Ion Proton.  The GEO accession number for the small RNA 
sequencing data presented in this study is GSE84525. 
 
2.1.4. TCGA training data set 
Bladder cancer RNA and miRNA-sequencing level 3 data was extracted from 
the TCGA data portal.  TCGA normalized RNAseq (RSEM) and miRNA-seq counts 
(RPM – reads per million mapped miRNA) were log2-transformed, median centered 
and filtered based on a fold change of or greater than 2 in at least 10% of the 
samples.   
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2.1.5. Consensus Clustering 
Messenger RNAs and miRNAs that passed the filtering criteria were used for 
hierarchical consensus clustering (CC) in the R package ConsensusClusterPlus, 
with 80% resampling and 1,000 iterations (74).  Read counts for both mRNAs and 
miRNAs were used as input for differential expression analysis in the R package, 
edgeR (75, 76).  All analyses utilized a false-discovery rate (FDR) cutoff of 5%, and 
a fold change cutoff of 2. 
 
2.1.6. Subtype Prediction 
Prediction analysis of microarrays (PAM) was used to identify the minimal 
number of mRNAs or miRNAs that could accurately predict subtype classification 
using TCGA’s cohort and the mRNA CC (k=2) calls as a reference (77).  The 
analysis resulted in a 593-mRNA predictor (Δ = 6.969), and a 63-miRNA predictor (Δ 
= 3.898), which was validated using the 62 FF cohort.   
 
2.1.7. Identification of downstream targets 
Potential downstream target mRNAs of the differentially expressed miRNAs 
were analyzed using Ingenuity Pathway Analysis miRNA target filter.  In order to be 
considered as an mRNA target, the mRNA and miRNA had to be negatively 
correlated.   
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2.1.8. Survival Analyses 
Clinical data for TCGA’s cohort was extracted from TCGA’s data portal, and 
survival curves were generated in GraphPad Prism 6.  
 
2.2. Methods for Chapter 4 
2.2.1. TCGA data 
Raw bladder cancer RNA-seq data (BAM files) and their related clinical data 
were downloaded from the Cancer Genomics Hub (CGHub) and TCGA data portal.  
The BAM files were converted to paired-end FASTQ files for each sample using 
bam2fastq.  The raw paired-end reads in FASTQ format were aligned to the human 
reference genome, GRCh37/hg19, using MOSAIK and saved as BAM files (78).  
Raw counts for each gene were then generated by counting the mapped reads in 
mRNAs and lncRNAs annotated in GENCODE15 using the HTSeq package.  We 
used the “union” mode in HTSeq to mask the overlapped regions between mRNA 
and lncRNA to overcome the issue of non-strand specific RNA sequencing in 
TCGA’s data.  Raw read count data were normalized using DESeq (79).  Messenger 
RNAs and lncRNAs were kept for subsequent analysis if their FPKM was equal to or 
above 1 in at least 10% of the samples.   
 
2.2.2. Differential expression analysis 
Differentially expressed mRNAs and lncRNAs were identified using DESeq in 
the R statistical programming environment (79).  Significantly differentially expressed 
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mRNAs and lncRNAs were identified using an FDR cutoff of or less than 5%, and 
fold change cutoff of or more than a 2-fold difference.   
 
2.2.3. LncRNA Consensus Clustering 
Consensus hierarchical clustering was performed with 500 runs and 80% 
resampling using the lncRNA expression data.  
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Contents of this chapter are based on Ochoa AE, Choi W, Su X, Siefker-Radtke A, 
Czerniak B, Dinney C, McConkey DJ.  2016.   Specific micro-RNA expression 
patterns distinguish the basal and luminal subtypes of muscle-invasive bladder 
cancer.  Oncotarget 7(49):80164-80174.   
Copyright permission not required since Oncotarget journal policy states that, 
“authors retain ownership of the copyright for their article.” 
 
3.1. Introduction and Rationale 
MIBC is a highly heterogeneous disease where approximately half of the patients 
respond to treatment, while the other half does not.  Recently, anti-PDL1 immune 
checkpoint inhibitor was approved for MIBC (5, 6), providing patients with an 
alternative treatment option.  While prognostication is based entirely on clinical and 
pathological criteria, several large-scale genomics projects have provided new 
insights into the molecular heterogeneity of MIBC.  The subtypes of MIBC that have 
been identified have shown similarities to the intrinsic molecular subtypes of breast 
cancers (4, 7, 8, 11).  The “basal” (or “squamous cell like”) subtype (80) is enriched 
with squamous histopathological features, and is often associated with advanced 
and metastatic disease at presentation along with shorter survival outcomes (4, 8, 
11).  The “luminal” (or “papillary”) subtype had overall better outcomes, are enriched 
with papillary histopathological features and activating FGFR mutations (4, 8, 11, 
81).  Since the basal and luminal subtypes of MIBC display distinct biological and 
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clinical differences, they should be treated differently.  Unfortunately, there are no 
reliable clinical tools that can quickly subtype MIBCs, revealing a true need in the 
field.   
One way to address the clinical need of a subtype identifier is to explore the 
miRNA expression profiles of basal and luminal MIBCs.  MiRNAs are attractive 
cancer biomarkers because of their stability in body fluids and FFPE tissues (82, 
83).  Since miRNA expression has primarily been explored in the context of tumor 
tissue versus normal tissue, we wondered whether miRNAs could also be used to 
identify basal and luminal molecular subtypes of MIBC.  In this chapter, we used 
TCGA’s matched whole genome mRNA and miRNA expression data and generated 
a new miRNA sequencing data set with 62 MIBCs from our own institution to explore 
the miRNA expression profiles of basal and luminal cancers.   
 
3.2. Results 
3.2.1. Identification of MIBC subtypes 
TCGA’s cohort is currently the largest, publicly available data set of high 
quality whole transcriptome (mRNA and miRNA) MIBC data with 405 tumors.  We 
started with TCGA’s RNA-seq data.  Using an unsupervised approach, we used 
hierarchical consensus clustering (CC) to determine whether previous conclusions 
about the molecular subtypes of bladder cancer were reproducible.  CC identified a 
three cluster (k=3) solution that best fit the data mathematically (Figure 4A), which 
was consistent with our previous conclusions (11).  The three CC clusters also 
showed high expression of the biomarkers associated with the basal, p53-like and 
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luminal subtypes previously identified (11).  While there were similar expression 
patterns, the CC subtype assignments were only 75% identical to the one-nearest 
neighbor (oneNN) classifier subtype assignments (Figure 4B) (11).  Most of the 
discrepancies were due to class switches between the p53-like and luminal tumors, 
which is consistent with previous conclusions (11).  Even though a three-cluster 
solution was mathematically optimal, the basal and luminal biomarker expression 
was almost mutually exclusive in the infiltrated tumors (Figure 4C/D), suggesting that 
a two-cluster (k=2) solution would be biologically accurate. 
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Figure 4: mRNA consensus clustering 3-cluster solution.  A. Unsupervised CC 
with TCGA’s cohort (n=405) identified a 3-cluster solution to be optimal.  B. 
Comparison of the mRNA CC subtype assignments to MDA oneNN subtype 
assignments (left), and to BASE47 assignments (right).  C. Visualization of the 
relative expression of MDA subtype biomarkers: basal biomarkers (top), luminal 
biomarkers (middle), p53-like biomarkers (bottom).  D. Visualization of the relative 
expression of BASE47 genes: basal mRNAs (top), luminal mRNAs (bottom).  
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 Consistent with the idea of a k=2 solution being biologically accurate (Figure 
5A), we observed excellent overlap (93%) with the subtype assignments made using 
an independent basal/luminal PAM classifier (7).  We also compared the 
basal/luminal assignments made by CC to the basal/luminal assignments made by 
oneNN, p53-like tumors were omitted, and observed 93% overlap (Figure 5B).  
Visualization of the basal and luminal biomarkers confirmed excellent separation of 
the basal and luminal CC subtypes.  However, a small fraction of the basal tumors 
that corresponded to some of the oneNN identified p53-like tumors, had noticeably 
lower expression of both basal and luminal biomarkers (Figure 5C/D).   
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Figure 5: mRNA consensus clustering 2-cluster solution.  A. Unsupervised CC 
with TCGA’s cohort (n=405) identified a 2-cluster solution.  B. Comparison of the 
mRNA CC subtype assignments to MDA oneNN subtype assignments (top), and to 
BASE47 assignments (bottom).  C. Visualization of the relative expression of MDA 
subtype biomarkers: basal biomarkers (top), luminal biomarkers (bottom).  D. 
Visualization of the relative expression of BASE47 genes: basal mRNAs (top), 
luminal mRNAs (bottom).  
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3.2.2. mRNA PAM classifier development 
 We used the TCGA mRNA data set and the k=2 CC subtype assignment as a 
training set, to develop our own mRNA PAM classifier.  For validation, we used 62 
samples from the MDA FF cohort (GSE48075, Table 2).  Since the whole genome 
expression profiling data was generated on two different platforms, we started with 
12,407 mRNAs that passed the filtering criteria in TCGA’s cohort and were present 
in the FF cohort to develop the PAM classifier.  PAM identified 593 mRNAs that 
optimally identified basal and luminal subtype classification, which contained 39 of 
the 47 BASE47 genes (Figure 6A).  There were a few discrepancies in the subtype 
assignments made using this new PAM classifier and BASE47, which were largely 
due to the presence of a small fraction of tumors that were double positive for basal 
and luminal biomarkers (Figure 6).   
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Characteristics of the MDA validation Cohort (n=62) 
 
  Total Basal Luminal p-value 
Cohort Size (n) 62 28 (45%) 34 (55%)  
Mean Age (y) ± SD 
68.7 ± 
9.9 69.8 ± 10.3 
67.9 ± 
9.6 0.686 
Clinical Stage at Specimen Collection 
(n)     
cT2 38 (61%) 17 (61%) 21 (62%) 0.774 
cT3 18 (29%) 9 (32%) 9 (26%)  
cT4 6 (10%) 2 (7%) 4 (12%)  
Positive Clinical Lymph Nodes (n) 10 (16%) 5 (18%) 5 (15%) 0.744 
Positive Clinical Metastasis (n) 5 (8%) 3 (11%) 2 (6%) 0.65 
Median Overall Survival (m) 46.30 18.70 82.40 0.073 
          
 
Table 2: Clinicopathologic characteristics of the MDA validation cohort (n=62).  
Summary of the clinical characteristics of the validation cohort used. The Mann-
Whitney U test was used to compare differences in mean age between groups.  The 
log-rank test was used to compare differences in survival between groups.  Fisher’s 
exact test was used to determine differences between groups for the remainder of 
categorical variables. 
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Figure 6: 593-mRNA PAM genes.  A. Visualization of the 593-mRNA PAM genes in 
TCGA’s cohort. B. Visualization of the 593-mRNA PAM genes in the FF cohort. 
Color bars: MDA – basal (red), luminal (blue), p53-like (green); BASE47 – basal 
(red), luminal (blue); mRNACC/PAM – basal (red), luminal (blue).  
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The 593 PAM mRNAs were then used to make subtype predictions on the 62 
FF cohort (Figure 6B), resulting in 28 basal tumors and 34 luminal tumors.  The 28 
predicted basal tumors encompassed all the basal tumors originally identified by the 
oneNN prediction, and had high expression of basal markers and basal BASE47 
genes (Figure 7).  The 34 predicted luminal tumors encompassed all the luminal 
tumors identified by oneNN prediction and had high expression of luminal markers 
and luminal BASE47 genes (Figure 7).   
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Figure 7: mRNA PAM classifier identifies basal and luminal tumors in 
validation cohort.  A. Visualization of the relative expression of MDA basal and 
luminal markers as a function of PAM identified subtype classification.  B. 
Visualization of the relative expression of BASE47 basal and luminal genes as a 
function of PAM identified subtype classification.  C. Comparison of mRNA PAM 
subtype assignments and MDA oneNN assignments. Color bars: oneNN – basal 
(red), luminal (blue), p53-like (green); PAM – basal (red), luminal (blue). 
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3.2.3. Identification of miRNA based subtypes 
After identifying the basal and luminal MIBCs in the two datasets, we 
characterized their differential miRNA expression patterns as a step toward 
identifying a miRNA-based signature that could distinguish the two subtypes.  We 
used the same unbiased approach, and used TCGA’s miRNA-seq data from 405 
MIBCs to perform consensus hierarchical clustering (Figure 8).  Using a k=2 solution 
(Figure 8A), similar to the mRNA analyses, we observed 77% and 73% concordance 
with the basal and luminal subtype assignments made by mRNA CC and BASE47, 
respectively (Figure 8B).  However, when we examined basal and luminal mRNA 
biomarker expression based on the miRNA clusters, we observed a significant 
fraction of the mRNA PAM-defined luminal tumors clustered with the miRNA-defined 
basal cluster (Figure 8C/D).   
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Figure 8: miRNA consensus clustering 2-cluster solution.  Unsupervised CC 
was performed with the miRNA expression from 405 tumors in TCGA’s cohort.  A. 
MiRNA CC identified 2 distinct clusters.  B. Comparison of miRNA CC subtype 
assignments to mRNA CC assignments (top), to BASE47 assignments (middle), and 
to MDA oneNN assignments (bottom).  C. Visualization of the relative expression of 
MDA basal and luminal markers.  D. Visualization of the BASE47 basal and luminal 
genes.  Color bars: miRNA CC – basal (purple), luminal (light blue); oneNN – basal 
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(red), luminal (blue), p53-like (green); BASE47 – basal (red), luminal (blue); 
mRNACC– basal (red), luminal (blue).  Note: Orange boxes in C and D indicate 
luminal tumors that are likely misclassified.  
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3.2.4. Developing a miRNA-based PAM classifier 
Due to the number of misclassifications using an unbiased miRNA approach, 
we concluded that a supervised approach based on the mRNA subtype calls would 
generate more accurate information.  Since there is only one publicly available 
miRNA-seq data set with matched mRNA expression data, we needed to generate a 
validation cohort.  We generated a new miRNA-seq data set by performing small 
RNA sequencing on 62 FF samples from MDA (11).  Using TCGA’s cohort as a 
training set, we used 412 miRNAs that passed filtering criteria in TCGA’s cohort and 
were present in the FF cohort to develop a miRNA-based PAM classifier.  PAM 
identified 63 miRNAs that optimally assigned samples to the basal and luminal 
subtypes identified by mRNA expression (Figure 9A/B).   
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Figure 9: miRNA PAM identifies basal and luminal tumors.  A. Visualization of 
the 63 miRNAs identified by PAM in TCGA’s cohort (n=405).  B. Visualization of the 
63 miRNAs identified by PAM in the FF validation cohort (n=62).  Color bars: oneNN 
– basal (red), luminal (blue), p53-like (green); BASE47 – basal (red), luminal (blue); 
mRNACC – basal (red), luminal (blue); mRNA/miRNA PAM – basal (red), luminal 
(blue).   
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We confirmed that these 63 miRNAs could accurately distinguish basal and 
luminal tumors using hierarchical clustering (Figure 10).  This resulted in 85% and 
83% concordance with the subtype assignments made by mRNA consensus 
clustering and BASE47, respectively.   
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Figure 10: Supervised hierarchical clustering with the 63 PAM miRNAs.  A. 
Hierarchical clustering was performed with the 63 PAM miRNAs in TCGA’s cohort, 
and the relative expression of the 63 miRNAs is depicted in the heatmap.  B. 
Hierarchical clustering was performed with the 63 PAM miRNAs in the FF validation 
cohort, and the relative expression of the 63 miRNAs is depicted in the heatmap.  
Color bars: oneNN – basal (red), luminal (blue), p53-like (green); BASE47 – basal 
(red), luminal (blue); mRNACC – basal (red), luminal (blue); mRNA/miRNA PAM – 
basal (red), luminal (blue).   
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3.2.5. miRNA expression patterns relate to basal/luminal biology 
 A survey of the results suggested that the known biological targets of the 
miRNAs were relevant to basal and luminal biology.  The basal tumors expressed 
high levels of miR-155, miR-142, miR-221, miR-222, and miR-223, which are 
miRNAs commonly associated with aggressiveness in other solid tumors and poor 
prognosis (84-88).  The luminal tumors expressed high levels of all the miR-200 
family members (miR-200a/b/c, miR-141, miR-429), consistent with previous 
findings in MIBC (4, 11).  Members of the miR-200 family are known inhibitors of 
EMT that directly target ZEB1 and ZEB2, core EMT transcription factors that directly 
inhibit transcription of the epithelial adhesion molecule E-cadherin (34).  Basal 
tumors are known to express high levels of ZEB1/2, while the luminal tumors 
express high levels of E-cadherin and low levels of ZEB1/2 (4, 11).  These findings 
are consistent with the idea that members of the miR-200 family play important roles 
in controlling the biological properties of the basal and luminal subtypes of MIBC.   
 
3.2.6. miRNA-mRNA relationships and relevance to bladder cancer biology 
 We used the Ingenuity Pathway Analysis miRNA target filter and miRTarBase 
to identify additional miRNA-mRNA relationships that were either experimentally 
observed or were highly predicted in the TargetScan database.  The results revealed 
that many of the basal subtype-associated miRNAs targeted mRNAs involved in 
adipogenesis, differentiation and EMT suppression (Figure 11A).  Specifically, 
several basal miRNAs (miR-125b, miR-142, miR-143, miR-152, miR-155 and miR-
221/222/223) have been predicted to target genes involved in adipogenesis and 
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RXR activation pathways (89-91).  Most notably, miR-125b, miR-223, miR-99a and 
miR-212 target FGFR2 and FGFR3, which are involved in luminal MIBC biology (4, 
91-93).  Several basal miRNAs (miR-125b, miR-142, miR-152, miR-146b, miR-222, 
miR-212) have also been predicted to target luminal factors that have been 
previously identified in breast cancer, including ERBB2, ERBB3, ERBB4 and FOXA1 
(94-96).  MiR-125b has also been predicted to inhibit homeobox (HOX) genes, which 
control urothelial terminal differentiation and are highly expressed by luminal MIBCs 
(97). 
 The miRNAs that were enriched in luminal MIBCs were predicted to target 
pathways associated with invasion and metastasis, including EMT, fibrosis and the 
actin cytoskeleton (Figure 11B).  For example, experimentally observed targets of 
miR-29c include 6 different collagens that are associated with fibrosis and possibly 
support cancer-associated fibroblast infiltration (98, 99).  MiR-10a, miR-20b and 
miR-301 were also predicted to target STAT3, while miR-1287 and miR-191 were 
predicted to target EGFR and IL6, respectively.  EGFR and IL6 are upstream 
regulators of STAT3, all of which have been implicated in basal breast and bladder 
cancers (100, 101).   
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Figure 11: Schematic representation of miRNA and mRNA target relationships.  
A. MiRNAs overexpressed in basal tumors (indicated in red text) target luminal 
genes (indicated in blue text) involved in differentiation, adipogenesis, and EMT 
suppression pathways.  B. MiRNAs overexpressed in luminal tumors (indicated in 
blue text) target basal genes (indicated in red text) involved in EMT, fibrosis, actin 
cytoskeleton, and basal gene expression pathways.  
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3.2.7. Subsets of basal and luminal MIBC 
 It was evident from the beginning that a subpopulation of the basal tumors 
expressed lower levels of both basal and luminal miRNAs, and this subpopulation 
corresponded to p53-like tumors identified by the oneNN classifier.  To explore this 
heterogeneity further, we utilized the class assignments from the TCGA 3-cluster (k 
= 3) mRNA CC solution to isolate the significant miRNAs and mRNAs that were 
differentially expressed by the “infiltrated” CC (Figure 12).  We identified 15 miRNAs 
by differential expression analysis that were overexpressed by the “infiltrated” 
cluster.  We analyzed the basal and luminal subtypes separately, and performed 
hierarchical clustering with the 15-miRNA signature.  In the basal subtype, we 
isolated 82% of the “infiltrated” tumors identified by mRNA CC (k=3), and in the 
luminal subtype we isolated 83% of the “infiltrated” tumors (Figure 12A).  The 
“infiltrated” luminal tumors identified by the 15-miRNA signatures likely correspond to 
TCGA’s cluster II, while the “infiltrated” basal tumors show similar expression 
patterns to TCGA’s cluster IV (4).   
 We applied the 15-miRNA signatures identified in TCGA’s cohort to the 62 FF 
cohort.  The basal and luminal tumors as identified by mRNA PAM were analyzed 
separately, and hierarchical clustering was performed with the 15-miRNA expression 
signature (Figure 12B).  In the basal subtype, all of the “infiltrated” tumors identified 
by mRNA CC (k=3) and the oneNN p53-like tumors clustered together.  In the 
luminal subtype, 89% of the “infiltrated” tumors identified by CC were isolated by 
hierarchical clustering.  The 15-miRNA signature includes miR-133b, miR-133a, 
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miR-143, miR-145, miR-99a and miR-100, which have been previously associated 
with fibrosis and chemo-resistance (102-104).   
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Figure 12: 15-miRNA signature identifies “infiltrated” subsets of the basal and 
luminal subtypes.  A. Hierarchical clustering was performed with the 15-miRNA 
signature in TCGA’s cohort.  The heatmaps depict relative expression of the 15-
miRNA signature.  (Left) Basal tumors identified by mRNA CC were isolated and 
subjected to supervised hierarchical clustering.  (Right) Luminal tumors identified by 
mRNA CC were isolated and subjected to supervised hierarchical clustering.  B. 
Hierarchical clustering was performed with the 15-miRNA signature in the FF 
validation cohort.  The heatmaps depict relative expression of the 15-miRNA 
signature.  (Left) Basal tumors identified by mRNA PAM were isolated and subjected 
to supervised hierarchical clustering.  (Right) Luminal tumors identified by mRNA 
PAM were isolated and subjected to supervised hierarchical clustering.  Color bars: 
oneNN – basal (red), luminal (blue), p53-like (green); mRNACC3 – basal (red), 
luminal (blue), “infiltrated” (green); mRNACC2 – basal (red), luminal (blue); PAM – 
basal (red), luminal (blue). 
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 3.2.8. Survival outcomes 
 Lastly, we assessed the survival outcomes based on the subtype 
assignments made using the 63 PAM miRNAs in TCGA’s cohort (n=405) to the 
mRNA based subtype assignments.  We compared the two-cluster solutions 
(BASE47, mRNA CC, miRNA PAM), and we observed that in all cases patients with 
basal tumors had the poorest clinical outcomes (Figure 13).  Having clinically 
available tests to prospectively identify patients with basal tumors is crucial, as our 
previous work showed that basal MIBCs responded well to platinum-based 
chemotherapy (11, 105). 
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Figure 13: Survival analyses confirm that basal tumors have poor survival 
outcomes.  Survival analyses performed with TCGA’s cohort (n=405) confirm that 
basal tumors identified by four different methods have poor survival outcomes.  A. 
Kaplan-Meier plot of overall survival based on MDA oneNN subtype assignments (p 
= 0.0012).  B. Kaplan-Meier plot of overall survival based on BASE47 subtype 
assignments (p = 0.0021).  C. Kaplan-Meier plot of overall survival based on mRNA 
CC subtype assignments (p = 0.0012).  D. Kaplan-Meier plot of overall survival 
based on 63-miRNA signature assignments (p = 0.0014).  
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3.3. Discussion 
 The first goal of this study was to confirm previous conclusions that had been 
made regarding the intrinsic subtypes of MIBC (4, 7, 11).  Using an unsupervised 
approach and a high-quality RNA-seq data set, we were able to reproduce our 
previous conclusion that a 3-subtype solution was mathematically optimal (11).  
However, one of the subtypes that corresponded to our original p53-like subtype, 
was unstable (11).  Since there were stability issues, we concluded that a two-
subtype solution corresponded better with the known biology.  We used 
unsupervised CC, and a k=2 solution, to develop a new mRNA PAM classifier.  The 
subtype identifications made by our new PAM classifier, were directly compared to 
the assignments made by BASE47 and revealed over 90% concordance.  We 
concluded that the basal and luminal subtypes of MIBC are highly robust, and most 
likely identify the intrinsic subtypes of bladder cancer.   
 The second part of this study was to develop a miRNA-based classifier that 
could be used to assign tumors to the molecular subtypes of MIBC.  Since miRNAs 
are considerably more stable in body fluids, including urine and blood, the 
development of a miRNA-based classifier present the possibility to perform tumor 
subtype calls with non-invasive techniques or “liquid biopsies”.  Also, miRNA 
expression profiling presents a new opportunity in the assessment of FFPE tissue 
sections, since the RNA isolated from these sections is often too degraded for 
sequencing techniques.  We used a supervised approach based on mRNA subtype 
classifications to identify 63 miRNAs that assigned tumors to the basal and luminal 
subtypes.  Analysis of the 63 miRNAs suggested that they may serve as robust 
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biomarkers, since their biological functions supported previous conclusions made 
about the biology underlying the basal and luminal subtypes.  Most of the 
overexpressed basal miRNAs targeted mRNAs implicated in the control of luminal 
biology (FOXA1, ERBB2), adipogenesis (FGFR2, FGFR3), and urothelial 
differentiation (HOX genes), which are down-regulated in the basal subtype.  The 
miRNAs overexpressed in the luminal subtype targeted transcription factors that 
control EMT (ZEB1/2), biomarkers associated with fibrosis and the actin 
cytoskeleton (collagens), and basal cancer biology (IL6, EGFR, STAT3), which are 
all suppressed in luminal cancers.  Using the 63-miRNA signature, were able to 
accurately assign MIBCs to the basal and luminal subtypes, and confirmed that the 
basal tumors were associated with poor outcomes.  We also identified a 15-miRNA 
signature that identified sub-populations within the basal and luminal subtype that 
appeared to be infiltrated with fibroblasts.  This signature could prove to be useful in 
identifying tumors that are resistant to traditional chemotherapy (11, 102, 106, 107), 
but are sensitive to immune checkpoint blockade (6).  
 Overall, we identified high concordance between the calls made using 
BASE47 and the new mRNA PAM classifier described here, demonstrating that 
subtype identifications made using relative mRNA expression are highly robust.  It is 
becoming common practice to sequence the tumors of every single patient.  Given 
the number of currently available subtype classifiers, it should become common 
clinical practice to subtype the tumors.  However, this can be difficult when using 
FFPE tissues, because of the variability in the quality of the RNA isolated.  Often 
times, samples are not usable because they do not pass standard quality control 
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cut-offs. The identification of a miRNA-based classifier presents new opportunities 
for subtype classification, since miRNAs are often stable in FFPE tissues and 
degraded RNA samples.  While the miRNA-based classifier does not appear to be 
as robust as an mRNA-based classifier, it could be used as an alternative strategy 
when samples do not pass quality checks.  A miRNA-based classifier could also be 
paired with an immunohistochemical classifier to confirm the subtype classifications 
(108).  Overall, the clinical identification of tumor subtype based on mRNA, miRNA, 
or immunohistochemistry should become part of routine diagnostic practices for 
MIBC in the near future.  
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Chapter 4: LncRNA expression subtypes in MIBC 
 
4.1. Introduction and Rationale 
Our understanding of cancer biology has transformed recently with the latest, 
large-scale cancer genomics projects that have been done.  Recent studies in MIBC 
have catalogued common DNA alterations that are present in MIBCs, and several 
groups also employed whole genome mRNA expression profiling to identify intrinsic 
basal and luminal subtypes of MIBCs that are similar to the corresponding subtypes 
of breast cancer (4, 7, 8, 11).  While several studies have focused on the impact of 
DNA mutations, copy number variations and translocations, non-protein coding 
RNAs have been overlooked on the large scale.   
Non-protein coding RNAs, including miRNAs and lncRNAs, have been shown 
to have a greater impact on evolutionary diversity than protein-coding mRNAs (109, 
110).  The effects of miRNAs on cancer biology have been studied, and their primary 
function is widely understood to inhibit expression of proteins encoded by their 
mRNA targets.  However, lncRNAs are a little more of a mystery since they are not 
as well understood, but have been observed to contribute to tumor initiation and 
progression (111-113).  While lncRNAs have been implicated in various biological 
functions, the mechanisms by which they exert their activity is largely unknown.  
Until recently, whole genome approaches to measure lncRNA expression patterns 
were not available, which has limited the scope of investigations to date.  In this 
chapter, we developed bioinformatic methods to extract whole genome lncRNA 
expression patterns from the TCGA’s RNA-seq data to examine whether we could 
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also identify lncRNA-based intrinsic subtypes of MIBC.  We seek to not only deepen 
our current understanding of MIBC biology, but to also identify potential biomarkers 
to clinically characterize the disease. 
 
4.2. Results 
4.2.1. Identification of lncRNA-based MIBC subtypes 
 We examined patterns of whole-genome lncRNA expression in TCGA’s MIBC 
RNA-seq dataset (n=407) by re-aligning and re-annotating the data.  A total of 
31,191 lncRNAs were isolated and analyzed. After filtering based on level of 
expression, 1,827 lncRNAs were found to be expressed by MIBCs.  We used the 
1,827 lncRNAs to perform unsupervised consensus clustering (CC) to determine the 
number of intrinsic lncRNA-associated molecular subtypes that were present.  The 
results revealed the presence of 3 distinct clusters (Figure 14A).  We compared the 
lncRNA subtypes to the mRNA based basal, luminal, and p53-like subtypes as 
identified by MDA’s oneNN model (11), and found 75% concordance.  We noticed 
that the third cluster identified by CC contained mixed expression of the basal and 
luminal specific mRNAs (Figure 14B), similar to our previous findings (114), 
suggesting a 2-cluster solution may be more robust. 
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Figure 14: LncRNA consensus clustering identifies a 3-cluster solution.  
LncRNA consensus clustering was performed with TCGA’s cohort (n=407) and a 3-
cluster solution was identified as mathematically optimal.  A. Consensus clustering 
results in 3 distinct clusters.  B. Visualization of MDA basal markers (top), MDA 
luminal markers (middle), and MDA p53-like tumors (bottom).  Color bars: PAM 
subtype – basal (red), luminal (green); Lund subtype – GU (red), Infil (green), SCCL 
(blue), UroA (purple), UroB(yellow); oneNN subtype – basal (red), luminal (green), 
p53-like (purple); lncRNA consensus clustering – basal (red), luminal (green), p53-
like (purple).  Relative expression of luminal genes GATA3 and PPARG are also 
visualized. 
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We chose to focus on a 2-cluster solution, focusing on the intrinsic basal and 
luminal subtypes, since these appeared to be more stable (Figure 15).  When the 
lncRNA-based basal and luminal subtypes were compared to the mRNA PAM-
identified basal and luminal subtypes (114), there was 98% concordance, 
suggesting that lncRNA expression alone could be used to identify the intrinsic basal 
and luminal subtypes of MIBC.  We also compared the lncRNA CC subtype 
identifications to the oneNN basal and luminal classifications, in the absence of the 
p53-like tumors (11), and we also see 98% concordance between the calls, 
suggesting the basal and luminal intrinsic subtypes are reproducible.   
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Figure 15: 2-cluster lncRNA consensus clustering solution.  LncRNA consensus 
clustering was performed with TCGA’s cohort, in the absence of “p53-like” tumors (n 
= 308) and a 2-cluster solution was identified.  A. LncRNA consensus clustering 
results in 2 distinct clusters.  B. Visualization of basal markers (top), cell cycle 
markers (middle - top), extracellular matrix markers (middle - bottom), and luminal 
markers (bottom).  Color bars: PAM subtype – basal (red), luminal (green); Lund 
subtype – GU (red), Infil (green), SCCL (blue), UroA (purple), UroB(yellow); oneNN 
subtype – basal (red), luminal (green), p53-like (purple); lncRNA consensus 
clustering – basal (red), luminal (green).  Relative expression of luminal genes 
GATA3 and PPARG are also visualized. 
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4.2.2. mRNA expression in the lncRNA-defined subtypes 
We used the mRNA expression patterns in the lncRNA-defined basal and 
luminal MIBCs to perform gene set enrichment analysis (GSEA).  The results 
indicated that the basal and luminal MIBC clusters identified by lncRNAs were very 
similar to basal and luminal breast cancers, as indicated by the significant 
enrichment of the CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP gene 
signature in the luminal subtype and 
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DOWN gene signature in 
the basal subtype (115).  Also, similar to previous reports in bladder and breast 
cancers, the basal subtype identified by lncRNA expression had overall poor survival 
when compared to the luminal subtype (4, 7, 11, 114) (Figure 16). 
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Figure 16: Survival outcomes based on the lncRNA defined basal and luminal 
clusters.  Kaplan-Meier plot of the overall survival outcomes of the lncRNA defined 
basal and luminal clusters in TCGA’s cohort (n = 308). The basal subtype exhibited 
overall poor survival outcomes (p = 0.038).  
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4.2.3. Differential lncRNA expression 
Differential expression analysis of the lncRNAs between the basal and 
luminal subtypes identified 430 lncRNAs to be significantly differentially expressed 
(Figure 17).  The basal subtype overexpressed 204 lncRNAs, while the luminal 
subtype overexpressed 226 lncRNAs.  A closer analysis of the differentially 
expressed lncRNAs identified some lncRNAs with previously established functional 
activity in cancer.  The basal subtype overexpressed several lncRNAs that have 
been previously studied, including MIAT, MEG3, and MIR155HG, while the luminal 
subtype overexpressed UCA1.  Interestingly, the basal subtype expressed 
MIR155HG, which has been associated with an aggressive phenotype and 
activation of epithelial-mesenchymal transition (EMT) (116).  There was also high 
expression of MEG3, which has been previously characterized as a tumor 
suppressor in bladder cancer since it is typically expressed by normal tissues and 
lost in bladder cancer (69, 117).  Urothelial carcinoma associated 1 (UCA1) has 
been identified as a biomarker for bladder cancer in urine sediment (65), and in this 
study, we found it to be significantly upregulated in luminal MIBC when compared to 
basal MIBCs.   
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Figure 17: Visualization of the 430 differentially expressed lncRNAs.  The 
heatmap depicts relative expression of the 430 significantly differentially expressed 
lncRNAs in TCGA’s cohort (n = 308).  Color bars: PAM subtype – basal (red), 
luminal (green); Lund subtype – GU (red), Infil (green), SCCL (blue), UroA (purple), 
UroB(yellow); oneNN subtype – basal (red), luminal (green), p53-like (purple); 
lncRNA consensus clustering – basal (red), luminal (green).  Relative expression of 
luminal genes GATA3 and PPARG are also visualized. 
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4.2.4. LncRNA-based PAM classifier 
 We next sought to develop a lncRNA-based PAM classifier, which could 
accurately identify the basal and luminal subtypes of MIBC. Using TCGA’s cohort 
and the lncRNA CC subtype identifications, PAM identified solutions ranging from 53 
(Δ = 8.678, overall error rate = 0.013) to 9 lncRNAs (Δ = 12.475, overall error rate = 
0.045) that would be optimal for assigning cluster membership (Figure 18). However, 
due to a lack of publicly available MIBC RNA-sequencing cohorts, the lncRNA-based 
PAM classifier could not be validated.  
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Figure 18:   LncRNA-based PAM classifier training.   A. PAM training solution 
with 53 lncRNAs (Δ = 8.678, overall error rate = 0.013).  B. PAM training solution 
with 28 lncRNAs (Δ = 9.763, overall error rate = 0.016).  C. PAM training solution 
with 17 lncRNAs (Δ = 10.848, overall error rate = 0.023).  D. PAM training solution 
with 9 lncRNAs (Δ = 12.475, overall error rate = 0.045).  Color bar: lncRNACC - 
basal (red), luminal (blue). 
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4.2.5. Identification of sub-clusters within the basal and luminal subtypes 
We further examined the presence of sub-clusters within the intrinsic basal 
and luminal lncRNA subtypes.  To study this, we performed unsupervised 
consensus clustering on the 137 basal tumors identified by lncRNA CC.  This 
revealed the presence of 2 clusters (Figure 19A).  We used canonical basal markers 
(KRT5, KRT6A, KRT6B, KRT6C) and markers of EMT (ZEB1/2, TWIST1, FN1) to 
classify the tumors as either “epithelial” or “mesenchymal” (Figure 20).  Comparison 
of the sub-clusters as identified by mRNA signature or lncRNA CC revealed 90% 
concordance.  There were 129 lncRNAs significantly differentially expressed 
between the two basal sub-clusters, 62 over-expressed by cluster2 (“epithelial”), and 
67 over-expressed in cluster1 (“mesenchymal”) (Figure 19B).  When comparing the 
two basal sub-clusters, there was a significant difference in survival outcomes 
(p=0.027), with the “mesenchymal” tumors showing poor outcomes (Figure 19C).   
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Figure 19: LncRNA consensus clustering identifies two subsets within the 
basal subtype.  The basal tumors identified by lncRNA consensus clustering were 
subjected to a second round of unsupervised consensus clustering.  A. Consensus 
clustering identifies two subsets within the basal subtype.  B. Visualization of the 129 
significantly differentially expressed lncRNAs between the two subsets.  C. Kaplan-
Meier plot shows that cluster1 (“mesenchymal” sub-cluster) exhibits poor overall 
survival outcomes (p = 0.027). Color bars: Lund subtype – GU (red), Infil (green), 
SCCL (blue), UroA (purple), UroB(yellow); basal subtype – epithelial (yellow), 
mesenchymal (purple), gray (data not available); lncRNA consensus clustering – 
cluster1 (red), cluster2 (light blue).  Relative expression of epithelial marker CDH1, 
and mesenchymal marker ZEB1 are also visualized. 
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Figure 20: Identification of basal sub-clusters by mRNA expression signature. 
Basal tumors in TCGA’s cohort of 408 patient samples were isolated using a PAM 
classifier based on mRNA expression.  Supervised hierarchical clustering with 
epithelial markers (top) and mesenchymal markers (bottom) identified two sub-
clusters of basal tumors.  Color bars: PAM subtype – basal (red); Lund subtype – 
GU (red), Infil (green), SCCL (blue), UroA (purple), UroB(yellow); oneNN subtype – 
basal (red), luminal (green), p53-like (purple); sub-cluster – epithelial (red), 
mesenchymal (yellow).  
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GSEA comparing the mRNA expression patterns between the two sub-
clusters confirmed a down-regulation of metastasis markers in the “epithelial” sub-
cluster (Figure 21).  We found the 
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP gene set 
(Figure 21A) (115), and the JAEGER_METASTASIS_DN gene set (Figure 21B) 
(118) to be significantly enriched in the “epithelial” basal subset.  We followed up this 
observation by generating an EMT lncRNA expression signature that was derived 
from cell line expression profiles that are currently available through the Cancer Cell 
Line Encyclopedia (CCLE).  Visualization of this signature showed relatively high 
expression of EMT lncRNAs in the mesenchymal sub-cluster (Figure 22A), and 
GSEA analyses showed significant enrichment of the down-regulated lncRNAs in 
mesenchymal cell lines in the “epithelial” sub-cluster (p = 0, FDR = 0) (Figure 22B).  
Interestingly, the “mesenchymal” sub-cluster had over-expression of two lncRNAs 
that are considered to be tumor suppressors, MIAT and MEG3 (60, 69, 117, 119), 
while the lncRNAs over-expressed in the “epithelial” sub-cluster have not been 
studied previously.  Again, we observed high expression of MEG3 was associated 
with poor overall survival.   
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Figure 21: The two subsets of the basal subtype are characterized by 
differences in expression of mesenchymal gene sets.  A. GSEA analyses 
identified significant enrichment of the 
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP gene set in the 
“epithelial” subset (p = 0, FDR = 0.00168).  B. GSEA analyses identified significant 
enrichment of the JAEGER_METASTASIS_DN gene set in the “epithelial” subset (p 
= 0, FDR = 0.00126). 
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Figure 22: EMT lncRNA expression signature in the basal subtype.  A. 
Visualization of the EMT lncRNA expression signature in the basal subtype identified 
by lncRNA expression.  B.  GSEA analyses with a signature of significantly down-
regulated lncRNAs in mesenchymal cell lines, showed significant enrichment in the 
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“epithelial” sub-cluster (p = 0, FDR = 0).  Color bars: Lund subtype – GU (red), Infil 
(green), SCCL (blue), UroA (purple), UroB(yellow); basal subtype – epithelial 
(yellow), mesenchymal (purple), gray (data not available); lncRNA consensus 
clustering – cluster1 (red), cluster2 (light blue).  Relative expression of epithelial 
marker CDH1, and mesenchymal marker ZEB1 are also visualized. 
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We performed the same unsupervised consensus clustering on the 171 
luminal tumors identified by lncRNA CC.  This revealed the presence of 2 clusters 
(Figure 23).  We opted to compare these two sub-clusters to the luminal subtypes 
previously identified by the Lund group, genomically unstable (GU) and urobasal A 
(UroA) (8).  Surprisingly, we found that one of the luminal sub-clusters contained 
only UroA tumors (cluster2), while the other sub-cluster contained a majority GU 
tumors along with some UroA tumors (cluster1).  We studied the differentially 
expressed lncRNAs between the two luminal sub-clusters, resulting in 191 
significant differentially expressed lncRNAs.  There were 58 up-regulated in the 
“UroA” sub-cluster, and 133 up-regulated in the “GU” sub-cluster (Figure 23B).  The 
“UroA” sub-cluster was enriched for MIR31HG and UCA1, while the “GU” sub-cluster 
was enriched for DNM3OS, SNHG18, and CDKN2B-AS1.  When looking at the two 
sub-clusters of luminal, there was no difference in survival outcomes (Figure 23C). 
GSEA comparing the two sub-clusters of the luminal subtype identified a 
significant difference in grade based on the presence of the 
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN gene set in the “UroA” tumors, 
and the LINDGREN_BLADDER_CANCER_CLUSTER_3_UP gene set in the “GU” 
tumors (120).  This suggested that the “UroA” sub-cluster was enriched with down-
regulated genes in high grade tumors (Figure 24A), and the “GU” sub-cluster was 
enriched with up-regulated genes in high grade tumors (Figure 24B).   
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Figure 23: LncRNA consensus clustering identifies two subsets within the 
luminal subtype.  The luminal tumors identified by lncRNA consensus clustering 
were subjected to a second round of unsupervised consensus clustering.  A. 
Consensus clustering identifies two subsets within the luminal subtype.  B. 
Visualization of the 191 significantly differentially expressed lncRNAs between the 
two subsets.  C. Kaplan-Meier plot shows no significant survival differences between 
the two subsets (p = 0.35).  Color bars: Lund subtype – GU (red), Infil (green), SCCL 
(blue), UroA (purple), UroB(yellow); basal subtype – epithelial (yellow), 
mesenchymal (purple), gray (data not available); lncRNA consensus clustering – 
cluster1 (red), cluster2 (light blue).  Relative expression of luminal markers GATA3 
and PPARG are also visualized. 
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Figure 24: The two subsets of the luminal subtype are characterized by 
differences in expression of high-grade bladder cancer gene sets.  A. The 
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN gene set is significantly 
enriched in the “UroA” tumors, suggesting that the “UroA” subset is enriched with 
tumors of a lower grade (p = 0, FDR = 0).  B. The 
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP gene set is enriched in the 
“GU” tumors (p = 0, FDR = 0.24), suggesting that the “GU” subset is enriched with 
high grade tumors.  
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4.2.6. Summary of differentially expressed lncRNAs 
We summarized the findings and identified 40 lncRNAs that were specific to 
the basal and luminal intrinsic subtypes, as well as to the sub-clusters identified 
within each intrinsic subtype (Figure 25). The top 10 lncRNAs identified to be 
overexpressed in the “UroA” sub-cluster were relatively expressed in the other 
luminal sub-cluster, but were down-regulated in the two basal clusters. The lncRNAs 
specific to the “GU” sub-cluster exhibited a similar pattern of expression, with slight 
expression in the other luminal sub-cluster and down-regulation in the two basal 
clusters. The lncRNAs overexpressed by the basal “epithelial” sub-cluster were 
significantly down-regulated in the basal “mesenchymal” sub-cluster, and exhibited 
relatively low expression across the other subsets.  While the lncRNAs specific to 
the basal “mesenchymal” sub-cluster were expressed by the basal “epithelial” sub-
cluster to a slightly lower degree, and were relatively down-regulated in the luminal 
clusters.   
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Figure 25: 40-lncRNA signature distinguishes the four lncRNA clusters.  The 
heatmap depicts relative expression of the 40 lncRNAs that distinguish the four 
lncRNA identified clusters.  Color bar: luminal – “UroA” (blue), luminal – “GU” (light 
blue), basal – “epithelial” (red), basal – “mesenchymal” (yellow).   
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4.3. Discussion 
Emerging evidence implicates long non-coding RNAs (lncRNAs) in the 
regulation of crucial biological processes in cancer.   Using unsupervised 
hierarchical analyses of whole genome lncRNA expression to identify intrinsic 
lncRNA subtypes of human muscle-invasive bladder cancers (MIBCs), we identified 
two lncRNA MIBC subtypes that were almost identical to the recently discovered 
intrinsic basal and luminal subtypes identified through mRNA expression profiling.   
The basal lncRNA subtype could be further subdivided into “epithelial’ and 
“mesenchymal” subtypes and the luminal lncRNA subtype could be further 
subdivided into “UroA” and “GU” subtypes.  We see a difference in survival 
outcomes between the sub-clusters of basal, but there is no survival difference 
between the sub-clusters of the luminal subtype.  However, GSEA did reveal a 
potential difference in tumor grade between the two luminal sub-clusters.   
Analysis of the significant differentially expressed lncRNAs will add a 
significant layer of complexity to our current understanding of MIBC development 
and progression.  The lncRNAs over-expressed in the basal subtype were 
commonly associated with squamous cancers or regulators of EMT.  Two of the 
basal lncRNAs, RP11-132A1.4 and RP11-357H14.19, were shown to be up-
regulated in hypopharyngeal squamous cell carcinomas and head and neck 
squamous cell carcinomas, respectively (121, 122).  RP11-357H14.19 also plays 
host to miR-196a, which is also over-expressed in basal MIBCs (122).  ZEB1-AS1 is 
overexpressed in esophageal squamous cell carcinomas, and is also associated 
with lymph node metastasis and poor overall survival and disease specific survival 
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(123).  Other over-expressed basal lncRNAs include DNM3OS, which is predicted to 
be under the control of TWIST1, a key regulator of EMT (124).  RP11-38P2.2 was 
also overexpressed in basal MIBCs and is predicted to be controlled by miR-205-5p, 
a common inhibitor of EMT by targeting ZEB1 (125).  However, it is also suggested 
that this lncRNA acts as a sponge RNA to interact with and suppress miR-205 
expression to maintain totipotency of cells (125).  The most interesting 
overexpressed lncRNA in the basal cancers was MEG3, which has been identified to 
possess tumor suppressive activity as it is lowly expressed in tumor tissues when 
compared to normal tissues (70, 126-128).  In this present study, we see that high 
expression of MEG3 is associated with a lethal sub-cluster of basal tumors, 
suggesting that more studies need to be done to determine the role of MEG3 in the 
progression of MIBC. 
Several lncRNAs overexpressed in the luminal subtype were associated with 
response to cisplatin or with better survival outcomes.  RP11-789C1.1 expression 
was associated with better survival outcomes in gastric cancers, lower rates of 
metastasis and lower tumor stage (129).  RP11-363E7.4 was upregulated after 
cisplatin exposure, and was associated with up-regulated p53 pathway genes (130).  
It has been shown that cisplatin treatment upregulates the expression of UCA1, and 
is further increased in cisplatin-resistant bladder cancer cells (131).  Studies have 
shown that over-expression increases cell viability during cisplatin treatment, 
whereas UCA1 knockdown partially overcomes drug resistance (131).  Since the 
detection of UCA1 in urine sediment has proven to be highly sensitive and specific 
for diagnosing bladder carcinoma, it may also be developed into a biomarker to 
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predict sensitivity to chemotherapy in MIBC (65).  UCA1 is also suggested to be 
regulated by CEBPA by ChIP analyses, a transcription factor found commonly up-
regulated in luminal MIBCs (132).  However, UCA1 has 3 different splice variants, 
one of which has been suggested to induce EMT and increase the migratory and 
invasive abilities of bladder cancer cells by repressing miR-145 expression (133).   
 Overall, we saw high concordance between the basal and luminal 
classifications made by using lncRNA and mRNA expression demonstrating that the 
intrinsic basal and luminal subtypes of MIBC are robust, and that lncRNA expression 
may serve as a surrogate for identifying mRNA based subtypes.  This study also 
introduces the potential of using relative lncRNA expression to identify tumor 
subtype.  Since the detection of one bladder cancer associated lncRNA in urine 
sediment has already been established, it should be reasonable to develop a urine 
based test to quantify lncRNA expression and subsequently identify tumor subtype 
non-invasively in the near future.   
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Chapter 5: 
Summary & Future Directions 
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5. Conclusions 
Taken together, this dissertation outlines new findings that add significant 
complexity to the currently understood biology underlying the heterogeneity of MIBC, 
but also reinforces the presence of intrinsic subtypes of MIBC.  This chapter will 
review the conclusions made from Chapters 3 and 4, and discuss possible future 
work to expand on the conclusions made.   
 
5.1. Summary 
Chapter 3: miRNA expression profiles identify subtypes of MIBC.  The 
work presented in Chapter 3 revolved around two major goals.  The first goal was to 
show that the previously identified intrinsic subtypes of MIBC were reproducible (4, 
7, 8, 11).  Previous findings were confirmed by subjecting unsupervised analyses to 
the largest, high-quality data set that is currently available for MIBC from TCGA 
(n=405).  We identified three clusters that were reminiscent of the clusters previously 
identified (11), including stable basal and luminal subtypes and an “infiltrated” 
unstable cluster.  We then developed an mRNA-PAM classifier that consisted of 593 
mRNAs, that was validated in 62 FF samples from our own MDA cohort 
(GSE48075).   
The second goal of this chapter was to identify miRNAs that could optimally 
distinguish the basal and luminal subtypes of MIBC, which could lead to the 
development of better diagnostic tools for MIBC.  Since there is only one MIBC 
cohort with matched mRNA and miRNA expression, TCGA’s cohort, there was a 
need to develop a validation cohort.  We performed miRNA-sequencing on a cohort 
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of 62 FF MIBCs, that we have matched whole genome expression profiling data for.  
An unsupervised approach using miRNA expression alone did not yield positive 
results, so using a supervised approach we were able to develop a 63-miRNA PAM 
classifier that identified basal and luminal tumors with more than 80% accuracy.  We 
noticed that the miRNA expression patterns of the basal and luminal subtypes 
reiterated known biological properties of the subtypes. 
 
Chapter 4: LncRNA expression profiles identify subtypes of MIBC. Since 
recent work has implicated lncRNAs in the regulation of the hallmarks of cancer, we 
sought to understand the lncRNA expression patterns that were associated with the 
basal and luminal subtypes of MIBC.  We extracted lncRNA expression data from 
TCGA’s RNA-seq data set (n=407), and performed unsupervised analyses.  Based 
solely on lncRNA expression we identified the basal and luminal subtypes with over 
95% accuracy.  The lncRNAs overexpressed by basal tumors were associated with 
transcription factors involved in EMT and associated with squamous cancers, which 
are both characteristics of basal MIBCs.  The overexpressed lncRNAs in luminal 
tumors were primarily associated with good outcomes, or the development of 
cisplatin resistance.   
We also identified subsets within the basal and luminal subtypes.  Within the 
basal subtype, we identified a larger subset that exhibited “epithelial” properties and 
a smaller subset that exhibited “mesenchymal” properties, which had poor survival 
outcomes.  The luminal subtype could be further subdivided into a “UroA” subtype, 
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and a “GU” subtype that is enriched with mRNA expression patterns of high grade 
bladder cancers.   
 
5.2. Future Directions 
 In order to expand upon the work presented here, there are several follow up 
experiments that could be performed.  First and foremost, the development of a 
clinical diagnostic tool is greatly needed and should be prioritized.  Since ncRNAs 
are considered to be relatively stable in bodily fluids, and lncRNAs have been 
previously measured in urine sediment, it should be feasible to develop a clinically 
relevant tool.  However, there are several obstacles that need to be addressed 
before development would be possible.  The first obstacle would be optimizing the 
RNA isolation protocol.  We would need to be able to acquire at least 100 ng of total 
RNA to perform a custom Nanostring assay with both miRNAs and lncRNAs, or 
more if miRNA-sequencing and RNA-sequencing is desired.  Once the isolation 
protocol is in place, we would need to decide on either a custom panel of miRNAs 
and lncRNAs that could identify the intrinsic subtypes or if we want to perform 
sequencing.  Lastly, we would need to perform an independent experiment to 
confirm that the expression profiles observed in the body fluids are comparable to 
the expression patterns observed in the primary tumor.  The test would then need to 
be validated and approved for clinical use. 
 Another important question that needs to be addressed is, which ncRNAs are 
the most important for basal and luminal gene expression in bladder cancer.  This 
question could be addressed by performing knockdowns of the most deregulated 
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ncRNAs in basal or luminal cell lines, followed by whole genome expression 
analysis.  If a phenotypic or transcriptomic subtype change were observed after 
knockdown, then that ncRNA may play an important role in regulating subtype 
expression profiles.  We may also opt to perform similar analyses in breast cancer, 
to determine which ncRNAs are specific to the basal and luminal subtypes of 
bladder cancer or to develop a test that could identify basal and luminal subtypes 
regardless of tumor site.  Once these ncRNAs are identified, the molecular 
mechanism by which they control gene expression would need to be explored.  This 
would be a tremendous undertaking, but it would help the research community 
understand the underlying biology of basal and luminal expression subtypes.  An 
important distinction that would need to be made is, are the ncRNAs controlling the 
transcription factors that are implicated as upstream regulators of the subtype, or are 
the ncRNAs regulating downstream expression of the upstream regulators.  This 
could lead to the subsequent identification of druggable targets, providing MIBC 
patients with additional treatment options. 
 Lastly, in order to complete the work presented in chapter 4, it will be 
important to develop a validation cohort to confirm our findings.  This could be 
addressed by performing RNA-sequencing on our cohort of 62 FF tissues, and 
subsequently using bioinformatic methods to isolate the lncRNA expression profiles.  
Ultimately, validating the lncRNA findings in an independent cohort will add a 
significant amount of relevance to this work.   
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5.3. Final Discussion 
When we look at the data presented as a whole, we see that the expression 
patterns of ncRNAs can provide insight into the basal and luminal MIBCs since we 
see similar characteristics of the subtypes regardless of RNA type used to identify 
subtype.  The results also indicate the presence of sub-clusters within the basal and 
luminal subtypes, which are distinguished by infiltration or the presence of 
mesenchymal markers.  However, a major question that remains is, how exactly do 
the identified miRNAs and lncRNAs affect the gene expression patterns observed 
that distinguish the basal and luminal subtypes of MIBC.   
One way to begin to address this question is to look at correlations between 
lncRNA and miRNA expression, as well as the mRNA targets of the miRNA.  Using 
TCGA’s cohort, we correlated the overexpressed lncRNAs in luminal tumors with 
miRNA expression.  We observed that several luminal lncRNAs were positively 
correlated with miR-934, miR-429, miR-200a and miR-200c, and was negatively 
correlated with miR-146b.  When we looked at the lncRNAs overexpressed in basal 
tumors, we see significant negative correlations with the miR-200 family members 
(miR-200a, miR-200b, miR-429, miR-141, miR-200c), and positive correlations with 
miR-142, miR-155, and miR-146b.  Based on our previous studies, we see that miR-
934, and miR-200 family members are overexpressed in luminal tumors, while miR-
146b, miR-142 and miR-155 are overexpressed in basal tumors (114).  While the 
function of miR-934 has not been elucidated, the other miRNAs identified have been 
implicated in EMT.  The miR-200 family directly target transcriptional activators of 
EMT, including ZEB1/2 (34), miR-155 is positively correlated with metastasis in 
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breast cancer (88, 134, 135), miR-146b has been implicated in promoting metastasis 
in some tissues and inhibiting metastasis in others (136, 137), and miR-142 has 
been implicated as a metastasis suppressor (138, 139).  
These results suggest that miRNAs and lncRNAs play a concerted effort to 
regulate gene expression.  MiRNAs have been shown to regulate lncRNAs by 
binding to regions similar to their mRNA targets causing lncRNA instability, and 
lncRNAs have been shown to regulate miRNA expression through multiple 
mechanisms.  LncRNAs can regulate miRNA function by acting as a sponge, can 
directly bind to miRNA to communicate with downstream RNA targets (140), and can 
compete with miRNA binding to alleviate mRNA suppression (141).  LncRNAs can 
also act as hosts to miRNAs, with approximately 10% of lncRNA genes playing host 
to miRNAs (142) either in an intron or exon. For example, the H19 lncRNA is a 
precursor for miR-675 that functions as a tumor suppressor by inhibiting cellular 
proliferation (143).  The interplay between miRNA expression and lncRNA 
expression implicates ncRNAs as vital modulators of gene expression, however the 
mechanisms by which they do so remain to be elucidated in MIBC.  
Most importantly, this work implicates both lncRNAs and miRNAs as potential 
diagnostic biomarkers in MIBC.  In particular, lncRNA expression analyses were 
highly consistent with mRNA expression analyses, suggesting an alternative method 
to diagnosing and characterizing MIBCs.  Also, due to their high specificity, lncRNA 
expression may be a better indicator of disease state.  
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